Abstract Background Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83. 2019). Patients typically respond to front line platinum-based doublet chemotherapy. https://unionlosangelers.shop/product-category/sweatpeants/